Electric Pulses Beat Heat and Cold at Turning Dead Tumor Cells Into Cancer Vaccines

Not all ways of killing a tumor are equal when it comes to waking up the immune system. A new study published in Bioengineering & Translational Medicine provides some of the clearest evidence yet that the type of energy used to destroy cancer cells—intense heat, deep freezing, or high-voltage electric pulses—profoundly shapes how well the immune system can subsequently recognize and attack that tumor. In a controlled laboratory comparison, irreversible electroporation, a technique that kills cells by rupturing their membranes with short electric pulses, outperformed both thermal ablation and cryoablation at activating dendritic cells and driving the proliferation of tumor-antigen-specific T cells, the central players in anti-cancer immunity.

Focal therapies are minimally invasive treatments that use energy to destroy solid tumors while sparing surrounding healthy tissue. Surgeons and interventional radiologists can choose among thermal ablation, which cooks tumor tissue at high temperatures; cryoablation, which freezes it; and irreversible electroporation, which perforates cell membranes with pulsed electric fields until the cells die without significant heating. Beyond simply eliminating the visible tumor, clinicians have become increasingly interested in the immunogenic side effects of these techniques. When tumor cells die in particular ways, they can release antigens and danger signals that prime the immune system, potentially generating systemic responses against metastases that were never directly treated. This has fueled numerous clinical trials combining focal ablation with immune checkpoint inhibitors.

Yet a fundamental question has remained unresolved: which ablation modality produces the most immunogenic cell death, and why? Clinical decisions about which technique to use are typically based on tumor location, size, and disease stage rather than on immunological considerations, largely because direct head-to-head comparisons of the immune consequences have been scarce. The optimal dosing, timing, and pairing of ablation with immunotherapy remain largely unknown. The new study, led by researchers at the University of Minnesota, set out to answer this question with a rigorously controlled in vitro platform that isolates the interaction between treated tumor cells and the immune machinery responsible for T cell priming.

The team used melanoma cells engineered to express ovalbumin, a well-characterized model antigen, allowing them to quantitatively track every step of immune processing. They exposed the B16-OVA melanoma cells to three treatment conditions designed to ensure complete cell death: heating at 50 degrees Celsius for 30 minutes, freezing at minus 80 degrees Celsius for 30 minutes, and irreversible electroporation using 99 pulses of 50 microseconds each at 1250 volts per centimeter. The resulting cell lysates were then fed to dendritic cells grown from mouse bone marrow, and those antigen-loaded dendritic cells were co-cultured with naive T cells from OT-I transgenic mice, whose CD8 T cells carry receptors specifically tuned to the SIINFEKL peptide derived from ovalbumin.

The results were striking. When dendritic cells were loaded with lysates from electroporated tumor cells, they drove proliferation in 91.5 percent of antigen-specific T cells at the highest cell equivalent dose tested, compared with roughly 60 percent for cryoablation and 51 percent for thermal ablation. A positive control using repeated freeze-thaw cycles in liquid nitrogen pushed proliferation to 98 percent. Electroporated lysates also induced the strongest expression of CD86, a key co-stimulatory molecule on dendritic cells, indicating more robust dendritic cell maturation. In short, the manner of cell killing—not just the fact of cell death—determined how vigorously the adaptive immune response was ignited.

Paradoxically, the treatment that produced the best T cell response was not the one that released the most antigen. Cryoablation liberated the greatest quantities of total protein, ovalbumin antigen, adenosine triphosphate, and high mobility group box 1, two well-known damage-associated molecular patterns that act as immune alarm signals. Cryoablation released about 1912 micrograms per milliliter of protein, more than four times the amount released by thermal ablation, and its antigen release exceeded the electroporation condition by nearly threefold. Thermal ablation, which denatures and aggregates proteins, released the least of everything. If antigen quantity were the sole determinant of immunogenicity, cryoablation should have won.

The explanation lies in the adjuvant-like qualities of the cellular debris. When the researchers supplemented a fixed amount of ovalbumin antigen with lysates from treated B16 cells that lacked the cognate antigen, the electroporation lysates still produced the strongest dendritic cell activation and T cell proliferation, reaching 75 percent activated and proliferating T cells compared with roughly 52 percent for both cryoablation and thermal ablation. This experiment isolated the non-antigen components of the lysate—damage-associated molecular patterns, cytokines, and chemokines—and showed that they can make or break immune priming. Electroporated cells released more of the T cell chemoattractant IP-10 and less of the immunosuppressive cytokine IL-10 than the other modalities, creating a biochemical milieu that favors dendritic cell maturation and effector T cell expansion.

The study also probed whether the energy treatments altered the antigen itself. When purified ovalbumin protein and SIINFEKL peptide were exposed to the same freezing, heating, and electroporation conditions, antigen presentation and T cell activation were essentially unchanged. This suggests that the immunological differences observed with whole tumor cells stem from the complex mixture of cellular contents released upon death, not from direct modification of the antigen molecule under these conditions. The researchers note that the lyophilized ovalbumin used is mostly monomeric and may resist the conformational changes that denaturing treatments can inflict on more complex proteins, a limitation they plan to address with native protein preparations in future work.

Perhaps the most clinically provocative finding concerns dose. T cell activation in the platform saturated at a defined antigen concentration, beyond which additional antigen provided no benefit and could even impair cell viability, reflecting the finite processing capacity of antigen-presenting cells. The authors caution that overtreatment with ablation—deliberately targeting a larger tumor volume to guarantee complete destruction—may be counterproductive from an immunological standpoint. Excessive ablation can also destroy local lymphatic architecture, preventing dendritic cells from ferrying high-quality antigens to draining lymph nodes. They advocate for precision ablation that balances tumor destruction with preservation of the peritumoral immune niche, and they highlight that electroporation may offer a dual advantage by preserving molecular integrity while leaving transport pathways to the adaptive immune system intact.

The work carries important caveats. An in vitro system cannot reproduce the immunosuppressive tumor microenvironment, the wound-healing response, or the vascular and systemic inflammatory effects that clinical ablation triggers, and the ovalbumin model does not fully mirror endogenous tumor antigens. Pulse parameters also matter: recent studies show that varying pulse width and frequency can shift cell death between apoptotic and pyroptotic programs, each with distinct immunological consequences. Still, by demonstrating that the fundamental quality of the immunogenic signal—not merely its quantity—determines immune priming, the study provides a mechanistic foundation for engineering focal therapies as in situ tumor vaccines and for rationally selecting which energy modality to pair with checkpoint blockade in the clinic.

Subject of Research: Comparative immunogenicity of focal tumor ablation modalities and their effects on antigen presentation and T cell activation

Article Title: Focal therapeutic conditions matter: How energy affects antigen presentation and T cell activation

Article References: Jiang, M., Shao, Q., Vallin, J., Shimizu, Y., Burbach, B., Azarin, S., & Bischof, J. (2026). Focal therapeutic conditions matter: How energy affects antigen presentation and T cell activation. Bioengineering & Translational Medicine, 11(5), Article e70152. https://doi.org/10.1002/btm2.70152

Image Credits: AI Generated

DOI: 10.1002/btm2.70152

Keywords: irreversible electroporation, cryoablation, thermal ablation, focal therapy, dendritic cells, T cell activation, antigen presentation, immunogenic cell death, damage-associated molecular patterns, cancer immunotherapy, B16 melanoma model, immune checkpoint inhibitors